Daily Archives: 18 July 2024

Disruption of Blood Flow and Vessel Wall Damage in Aortic Dilation

Blood circulates through the body and is pumped by the heart into the aorta approximately once a minute. The aorta, the body’s main artery, receives blood from the heart with each heartbeat.

Aortic dilation can affect any part of the aorta, although the exact mechanism remains unclear. One theory suggests that weakening the connective tissue in the vessel wall may contribute. High blood pressure, age, and genetic predispositions increase the likelihood of aortic dilation. Most individuals with this condition do not experience symptoms, often leading to discovery during routine medical examinations.

Filip Hammaréus, a PhD student at Linköping University and intern physician at Ryhov County Hospital, notes the increasing use of imaging in healthcare. Imaging frequently identifies slightly enlarged aortas. However, a minority of cases may progress to severe dilation, potentially leading to aortic rupture, a life-threatening condition.

Regular monitoring of aortic diameter helps assess risk; larger diameters correlate with higher risks. Preventive surgery is sometimes recommended to prevent complications, although rupture can occur unexpectedly before surgery becomes necessary. Innovations in diagnostic tools are crucial for identifying at-risk patients early, improving personalised treatment strategies and reducing costs.

Petter Dyverfeldt, a professor at Linköping University, highlights ongoing research published in the European Heart Journal—Cardiovascular Imaging. This research aims to develop new methods for assessing risk and disease severity beyond aortic diameter measurements.

Normal blood flow exerts a crucial frictional force on the vessel wall, influencing the health of specialised cells within. Changes in blood flow patterns, particularly abnormal or reduced flow, may signal cellular changes leading to vessel wall weakening.

Advanced imaging techniques, such as 4D flow MRI, allow researchers to visualise blood flow dynamics and their impact on the vessel wall. In recent studies, researchers have observed associations between abnormal blood flow patterns in the aortic wall and elevated levels of inflammatory markers and proteins involved in connective tissue metabolism.

According to Filip Hammaréus, these findings build on existing research by demonstrating previously unexplored connections between blood flow dynamics, inflammation, and connective tissue turnover in patients with a dilated aorta. This novel approach combines magnetic resonance imaging with blood biomarker analysis, providing new insights into disease mechanisms.

Petter Dyverfeldt emphasises that traditional measures like aortic diameter alone may not capture the full complexity of aortic dilation. The study’s findings underscore the importance of integrating advanced imaging and biomarker analysis to enhance understanding and management of this condition.

Ongoing research is expanding our understanding of aortic dilation beyond conventional measures. By investigating the intricate relationships between blood flow dynamics, inflammation, and connective tissue metabolism, researchers aim to refine diagnostic and therapeutic approaches, ultimately improving outcomes for individuals with this complex cardiovascular condition.

More information: Filip Hammaréus et al, Wall shear stress measured with 4D flow CMR correlates with biomarkers of inflammation and collagen synthesis in mild-to-moderate ascending aortic dilation and tricuspid aortic valves, European Heart Journal – Cardiovascular Imaging. DOI: 10.1093/ehjci/jeae130

Journal information: European Heart Journal – Cardiovascular Imaging Provided by Linköping University

Potential Benefits of Novel Weight Loss Medication on Blood Pressure in Adults with Obesity

Leave a Reply

A study highlighted in the journal Hypertension indicates promising benefits of tirzepatide, a novel weight loss medication, in reducing systolic blood pressure among obese adults. Over eight months, the research involved nearly 500 participants who showed significant decreases in systolic blood pressure while using tirzepatide. This medication operates by mimicking glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, thereby enhancing insulin secretion and sensitivity post-meal, which aids in regulating blood sugar levels, slowing digestion, and curbing appetite—ultimately leading to weight loss.

Systolic blood pressure, the higher number in a blood pressure reading, holds more excellent predictive value for cardiovascular mortality than diastolic pressure. According to the American Heart Association’s 2024 statistics, 47% of adults in the United States are afflicted with hypertension, with nearly 42% classified as obese. These statistics underscore the critical need for effective treatments that concurrently address both conditions.

Tirzepatide gained initial approval from the FDA in 2022 for managing Type 2 diabetes and subsequently received approval in late 2023 for chronic weight management in adults with obesity or overweight who have related health conditions like hypertension and diabetes. This dual approval highlights its potential to mitigate multiple health risks associated with obesity, including high blood pressure.

Lead author Dr James A. de Lemos, from UT Southwestern Medical Center, Dallas, noted the study’s findings suggest that tirzepatide not only aids in weight loss but also shows impressive reductions in blood pressure among participants. The study, a planned sub-study within the larger SURMOUNT-1 trial, focused on assessing tirzepatide’s impact on blood pressure using 24-hour ambulatory monitoring in individuals with obesity but without Type 2 diabetes.

Participants in the sub-study were randomly assigned to receive either tirzepatide at varying doses (5 mg, 10 mg, or 15 mg) or a placebo. The results after 36 weeks revealed dose-dependent reductions in systolic blood pressure: 7.4 mm Hg for the 5 mg dose, 10.6 mm Hg for the 10 mg dose, and 8.0 mm Hg for the 15 mg dose. These reductions were consistent across participant subgroups categorized by age, sex, BMI, and hypertension-related risk factors.

Ambulatory blood pressure monitoring, which provides more comprehensive data than traditional office measurements, was used throughout the study. This method involved continuous monitoring over 24 to 27 hours, capturing daytime and nighttime readings. The study’s rigour ensured robust data analysis, though limitations included its subset nature and the limited frequency of nighttime readings.

Dr Michael E. Hall, commenting on the broader implications, highlighted the potential of tirzepatide and similar medications in not only addressing obesity-related complications but also potentially reducing cardiovascular risks associated with conditions like hypertension and diabetes. However, he emphasized the need for further research to ascertain long-term cardiovascular outcomes and the effects on blood pressure post-medication cessation.

In conclusion, the study underscores tirzepatide’s dual benefits in weight management and blood pressure reduction among obese individuals. Future investigations will be crucial in elucidating its sustained effects and broader implications for cardiovascular health, offering hope for improved management strategies against rising global obesity-related health challenges.

More information: James A. de Lemos et al, Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy, Hypertension. DOI: 10.1161/HYPERTENSIONAHA.123.22022

Journal information: Hypertension Provided by American Heart Association

Nutritional Therapy Outperforms Medication in Managing Irritable Bowel Syndrome

Leave a Reply

Irritable bowel syndrome (IBS) is a prevalent condition characterised by abdominal pain, gas, bloating, diarrhoea, and constipation, occurring in varying combinations and intensities. Treatment typically involves dietary recommendations, such as consuming smaller, more frequent meals and avoiding triggers like coffee, alcohol, and carbonated drinks. Medications may also alleviate gas, constipation, diarrhoea, bloating, or pain. In some cases, antidepressants are used to manage symptoms effectively.

A recent study published in The Lancet Gastroenterology & Hepatology compared three treatment approaches: two dietary interventions and one medication-based regimen. The study was conducted at Sahlgrenska University Hospital in Gothenburg and focused on adult patients with moderate to severe IBS symptoms.

Superior symptom relief through dietary adjustments was evident. The first group received traditional nutritional advice for IBS, emphasising changes in eating habits coupled with a low intake of fermentable carbohydrates, known as FODMAPs. These include lactose-containing products, legumes, onions, and grains, which ferment in the colon and can exacerbate IBS symptoms.

The second group followed a low-carbohydrate diet rich in protein and fats. The third group received optimised medication based on their most bothersome IBS symptoms. Each group comprised approximately 100 participants undergoing four-week treatment periods. Evaluation using a standardised IBS symptom scoring scale revealed compelling results.

Among those receiving traditional dietary advice and low FODMAP intake, 76% experienced significant symptom reduction. In the low-carbohydrate, high-protein and fat diet group, this figure was 71%, while in the medication group, 58% reported improvement.

Furthermore, all groups reported enhanced quality of life, reduced physical symptoms, and alleviated anxiety and depression symptoms. At a six-month follow-up, even after participants in the dietary groups had partially reverted to their previous eating habits, a substantial number continued to experience clinically meaningful symptom relief: 68% in the traditional nutritional advice and low FODMAP group and 60% in the low-carbohydrate diet group.

The study, led by Sanna Nybacka, Researcher and Dietician, Associate Professor Stine Störsrud, and Professor Magnus Simrén, all from Sahlgrenska Academy, University of Gothenburg, underscores the pivotal role of diet in managing IBS. It highlights the effectiveness of personalised treatment approaches and calls for further investigation into predictive factors for optimal treatment outcomes.

“In this study, we demonstrate the central role of diet in IBS treatment, alongside effective alternative therapies,” explains Sanna Nybacka. “Future research aims to refine personalised treatment strategies for IBS, identifying factors that may influence individual responses to different treatment modalities,” she concludes.

More information: Sanna Nybacka et al, A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial, The Lancet Gastroenterology & Hepatology. DOI: 10.1016/S2468-1253(24)00045-1

Journal information: The Lancet Gastroenterology & Hepatology Provided by University of Gothenburg

Research Investigates Influence of Workplace Genetic Testing on Employee Health Habits

Leave a Reply

Genetic testing remains a novel addition to workplace wellness initiatives, yet its potential implications are profound. Researchers from The Jackson Laboratory and the University of Michigan have embarked on a study aimed at uncovering the effects of integrating genetic testing into corporate health programmes while addressing the ethical and social considerations accompanying such advancements.

Their research, scheduled for publication in the August issue of Genetics in Medicine, offers a glimpse into how employees perceive and respond to employer-sponsored genetic testing initiatives. This study captures real-world perspectives following workplace genetic testing (wGT). It provides valuable insights into the decision-making processes of employers who contemplate incorporating genetic testing into their wellness strategies.

“Genetic testing could herald a new era in personal health management,” remarked Kunal Sanghavi, MBBS, M.S., CGC, Associate Director of Genetic Counseling at The Jackson Laboratory for Genomic Medicine, a key leader in the study. “Our findings are particularly pertinent as we explore genetic markers and their application in personalised medicine, potentially revolutionising targeted healthcare delivery.”

The survey-based study engaged participants from an extensive healthcare system encompassing approximately 30,000 employees; all offered genetic testing as part of their workplace benefits starting in the autumn of 2018. Conducted through a third-party service, this testing encompassed genes linked to heightened risks of cancer and heart disease and pharmacogenomic markers that influence medication responses and side effects.

Of the 776 respondents to the web survey, 418 opted for genetic testing and subsequently received their results. The survey collected data on their healthcare utilisation and behavioural changes post-testing. Notably, 12% of those tested discovered elevated cancer risks, while 9.5% identified heightened risks for heart disease. These individuals were significantly more inclined to seek medical advice (8.6 times more likely) and make lifestyle adjustments (3.23 times more likely), underscoring the potential behavioural impact of genetic insights.

“Many participants expressed that receiving their genetic results satisfied their curiosity about their health (74.7%),” noted Elizabeth Charnysh, M.S., CGC, a genetic counsellor at The Jackson Laboratory and the study’s lead author. She highlighted that individuals with negative results, indicating no increased risks, often found reassurance in their health status. However, Charnysh cautioned that genetic testing results should not overshadow other factors influencing disease risks, such as lifestyle choices and family medical history, a crucial point to keep in mind.

The study forms part of a broader initiative titled “Ethical, Legal, Social and Policy Implications of Workplace Genetic Testing,” spearheaded by Charles Lee, PhD, FACMG, and Scott Roberts, PhD, at The Jackson Laboratory and the University of Michigan, respectively. This multifaceted project aims to gather comprehensive insights from employees and employers regarding genetic testing in corporate settings, aiming to shape future workplace genetic testing policies nationwide.

“Understanding employee perspectives on workplace genetic testing is crucial,” explained Roberts, a professor of Health Behavior and Health Education at the University of Michigan. “While it’s encouraging to see proactive health behaviours among those at increased disease risks, further research will determine if these benefits are sustained over time.”

The study not only illuminates the potential benefits of workplace genetic testing but also raises important ethical considerations. Issues such as privacy, the potential for undue stress from test results, and the equitable distribution of healthcare resources are critical areas that demand further exploration. However, the promising potential of workplace genetic testing for personalised health management should instil optimism. Insights gleaned from this research will inform future genetic testing initiatives, ensuring they are ethically sound and maximise potential health benefits while minimising potential harms.

While workplace genetic testing holds promise for personalised health management, its integration into corporate wellness programmes must be approached thoughtfully and ethically. The ongoing research by The Jackson Laboratory and the University of Michigan represents a significant step towards understanding and harnessing the potential of genetic information in the workplace, paving the way for informed policies prioritising employee health and wellbeing.

More information: Elizabeth Charnysh et al, Health care utilization and behavior changes after workplace genetic testing at a large US health care system, Genetics in Medicine. DOI: 10.1016/j.gim.2024.101160

Journal information: Genetics in Medicine Provided by Jackson Laboratory